Related references
Note: Only part of the references are listed.Effects of the mGluR2/3 agonist LY379268 and the mGluR5 antagonist MPEP on handling-induced convulsions during ethanol withdrawal in mice
M. Foster Olive et al.
ALCOHOL (2008)
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease
Naomi P. Visanji et al.
FASEB JOURNAL (2008)
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)
Matthew J. Fell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Identification of a serotonin/glutamate receptor complex implicated in psychosis
Javier Gonzalez-Maeso et al.
NATURE (2008)
Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain
Maria Osikowicz et al.
PAIN (2008)
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity
M. L. Woolley et al.
PSYCHOPHARMACOLOGY (2008)
Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in Post-MPTP-induced parkinsonism via activation of tyrosine kinase receptor signaling pathway
Silvia A. Mandel et al.
NEUROCHEMICAL RESEARCH (2007)
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T. Patil et al.
NATURE MEDICINE (2007)
The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection
Corrado Corti et al.
JOURNAL OF NEUROSCIENCE (2007)
GDNF family receptor complexes are emerging drug targets
Maxim M. Bespalov et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action
Andreas Schober et al.
NEUROBIOLOGY OF DISEASE (2007)
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Giuseppe Battaglia et al.
JOURNAL OF NEUROSCIENCE (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Metabotropic glutamate receptors in the basal ganglia motor circuit
PJ Conn et al.
NATURE REVIEWS NEUROSCIENCE (2005)
Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice:: reversal by the mGLU2/3 receptor agonist LY379268
B Greco et al.
PSYCHOPHARMACOLOGY (2005)
Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP
JA Aguirre et al.
BRAIN RESEARCH (2005)
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor
JT Slevin et al.
JOURNAL OF NEUROSURGERY (2005)
Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex
N Belluardo et al.
NEUROSCIENCE (2005)
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
G Battaglia et al.
JOURNAL OF NEUROSCIENCE (2004)
The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease
J Schlefer et al.
BRAIN RESEARCH (2004)
Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
G Battaglia et al.
NEUROPHARMACOLOGY (2003)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease
JH Kordower
ANNALS OF NEUROLOGY (2003)
The GDNF family: Signalling, biological functions and therapeutic value
MS Airaksinen et al.
NATURE REVIEWS NEUROSCIENCE (2002)
DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury
JL Venero et al.
NEUROSCIENCE (2002)
Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs
V Bruno et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2001)
被撤回的出版物: Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways (Retracted article. See vol. 129, pg. 1035, 2014)
M D'Onofrio et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction
ER Matarredona et al.
JOURNAL OF NEUROCHEMISTRY (2001)
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat
L Dawson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
